ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
1 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
2 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
2 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
TTE
|
23K |
13M |
3 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
23K
|
13M
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Why IXC is a Strong BUY awaiting Phase 2 results in March 2020
|
|
TTE
|
46 |
18K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
46
|
18K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
1 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
1 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
5 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
7 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
7
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
TTE
|
23K |
13M |
8 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
23K
|
13M
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
2 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
1 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
TTE
|
23K |
13M |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
23K
|
13M
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
12 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
9 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
1 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
0 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
0
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
5 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
6 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
10 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Submits Completed BLA for Ryoncil to US FDA
|
|
TTE
|
121 |
82K |
1 |
03/02/20 |
03/02/20 |
ASX - By Stock
|
121
|
82K
|
1
|
|
ASX - By Stock
|
BUD |
Re:
Charts - BUD
|
|
TTE
|
424 |
189K |
1 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
424
|
189K
|
1
|
|
ASX - By Stock
|
BUD |
Re:
Charts - BUD
|
|
TTE
|
424 |
189K |
4 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
424
|
189K
|
4
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Investor Presentation
|
|
TTE
|
24 |
15K |
1 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
24
|
15K
|
1
|
|
ASX - By Stock
|
BUD |
Re:
Charts - BUD
|
|
TTE
|
424 |
189K |
2 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
424
|
189K
|
2
|
|
ASX - By Stock
|
BUD |
Re:
Charts - BUD
|
|
TTE
|
424 |
189K |
1 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
424
|
189K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 4C - quarterly
|
|
TTE
|
135 |
88K |
3 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
135
|
88K
|
3
|
|
ASX - By Stock
|
BUD |
Re:
Charts - BUD
|
|
TTE
|
424 |
189K |
1 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
424
|
189K
|
1
|
|
ASX - By Stock
|
BRN |
Re:
Ends December quarter with more than $1B in cash
|
|
TTE
|
13 |
8.1K |
4 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
13
|
8.1K
|
4
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
TTE
|
23K |
13M |
1 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
23K
|
13M
|
1
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB Trading - 2020
|
|
TTE
|
23K |
13M |
7 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
23K
|
13M
|
7
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Investor Presentation
|
|
TTE
|
24 |
15K |
3 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
24
|
15K
|
3
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Investor Presentation
|
|
TTE
|
24 |
15K |
1 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
24
|
15K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Investor Presentation
|
|
TTE
|
24 |
15K |
1 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
24
|
15K
|
1
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Investor Presentation
|
|
TTE
|
24 |
15K |
2 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
24
|
15K
|
2
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Investor Presentation
|
|
TTE
|
24 |
15K |
5 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
24
|
15K
|
5
|
|
ASX - By Stock
|
CYP |
Re:
Ann: Cynata Investor Presentation
|
|
TTE
|
24 |
15K |
2 |
31/01/20 |
31/01/20 |
ASX - By Stock
|
24
|
15K
|
2
|
|